Drug
ALK-001
ALK-001 is a pharmaceutical drug with 3 clinical trials. Currently 2 active trials ongoing.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
2(67%)
Phase Distribution
Ph phase_2
2
67%
Ph phase_3
1
33%
Phase Distribution
0
Early Stage
2
Mid Stage
1
Late Stage
Phase Distribution3 total trials
Phase 2Efficacy & side effects
2(66.7%)
Phase 3Large-scale testing
1(33.3%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
2
trials recruiting
Total Trials
3
all time
Status Distribution
Active(3)
Detailed Status
Enrolling by invitation1
Recruiting1
Active, not recruiting1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
2
Success Rate
N/A
Most Advanced
Phase 3
Trials by Phase
Phase 22 (66.7%)
Phase 31 (33.3%)
Trials by Status
enrolling_by_invitation133%
recruiting133%
active_not_recruiting133%
Recent Activity
2 active trials
Showing 3 of 3
recruitingphase_3
Study of ALK-001 on the Progression of Stargardt Disease
NCT07419334
active_not_recruitingphase_2
Open-Label Extension: Tolerability and Effects of ALK-001 on Stargardt Disease (TEASE)
NCT04239625
enrolling_by_invitationphase_2
Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease
NCT02402660
Clinical Trials (3)
Showing 3 of 3 trials
NCT07419334Phase 3
Study of ALK-001 on the Progression of Stargardt Disease
NCT04239625Phase 2
Open-Label Extension: Tolerability and Effects of ALK-001 on Stargardt Disease (TEASE)
NCT02402660Phase 2
Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3